The takeaway
Relmada Therapeutics Inc shows a pronounced seasonal pattern over 10 years of data — strongest in April (+17.9%) and softest in June (−11.8%).
Right now
In July, the stock has risen 60% of years, averaging +3.8%, about +1.7 pts better than the S&P 500.
The full picture
Relmada Therapeutics Inc's most dependable month has been April, higher in 8 of 10 years; June has been its least reliable, up just 10% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in April (+16.3 pts); it has trailed the market most in June (−12.0 pts).
“vs S&P” is Relmada Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Relmada Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, April has closed higher 60% of the time versus 80% across the last 10 years — the pattern is weakening.
Figures are the typical (median) April return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Dependability is the through-line here. April stands out, higher in 8 of 10 Aprils, but it heads a clutch of months that pull the year reliably upward.
The headline flatters a touch — its +17.9% average sits well above the +10.9% a typical year delivers, the work of a few big Aprils. That reliability comes with real swings, mind — even April ranges by 30.0% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: April has cleared the S&P 500 by +16.3 points above the index. That consistency sets it apart from the field, where the average stock manages April only about 55% of the time.
A few other months pull their weight: March, July, and September have also closed higher more often than not. At the other end of the calendar, June has been the soft spot — the weakest of 3 months that average a loss (−11.8%), and the edge isn't year-round — the stock has trailed the S&P 500 in June, January, and February. Its roughest month on record was a −84.2% December in 2024 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, April's last five years slipping below its longer-run record.
The takeaway is less about when to buy than what to expect: April aside, the stock's months offer little reliable tilt. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (April), its worst (June), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (April, +17.9%) has run well ahead of its worst (June, −11.8%) — the heatmap above shows how steady that gap has been year to year.
April has been the strongest, averaging +17.9% and closing higher in 8 of 10 years since 2016.
It's the weakest, averaging −11.8% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade